Gracell Biotechnologies GRCL Stock
Gracell Biotechnologies Price Chart
Gracell Biotechnologies GRCL Financial and Trading Overview
| Gracell Biotechnologies stock price | 10.25 USD |
| Previous Close | 5.73 USD |
| Open | 5.62 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 5.38 - 6.19 USD |
| 52 Week Range | 1.4 - 6.99 USD |
| Volume | 875.63K USD |
| Avg. Volume | 217.89K USD |
| Market Cap | 395.46M USD |
| Beta (5Y Monthly) | -1.857638 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.86 USD |
GRCL Valuation Measures
| Enterprise Value | -706636096 USD |
| Trailing P/E | N/A |
| Forward P/E | -3.4352942 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.32667673 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.241 |
Trading Information
Gracell Biotechnologies Stock Price History
| Beta (5Y Monthly) | -1.857638 |
| 52-Week Change | 38.06% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.99 USD |
| 52 Week Low | 1.4 USD |
| 50-Day Moving Average | 2.56 USD |
| 200-Day Moving Average | 2.55 USD |
GRCL Share Statistics
| Avg. Volume (3 month) | 217.89K USD |
| Avg. Daily Volume (10-Days) | 763.55K USD |
| Shares Outstanding | 67.72M |
| Float | 26.9M |
| Short Ratio | 1.72 |
| % Held by Insiders | 23.41% |
| % Held by Institutions | 55.52% |
| Shares Short | 268.42K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.40% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.17% |
| Return on Equity (ttm) | -41.66% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -569284992 USD |
| Net Income Avi to Common (ttm) | -600654016 USD |
| Diluted EPS (ttm) | -1.18 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.28B USD |
| Total Cash Per Share (mrq) | 18.86 USD |
| Total Debt (mrq) | 182.62M USD |
| Total Debt/Equity (mrq) | 15.09 USD |
| Current Ratio (mrq) | 6.261 |
| Book Value Per Share (mrq) | 17.877 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Gracell Biotechnologies
| Country | United States |
| State | N/A |
| City | Suzhou |
| Address | Building 12, Block B |
| ZIP | 215123 |
| Phone | 86 512 6262 6701 |
| Website | https://www.gracellbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 314 |
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China.
Q&A For Gracell Biotechnologies Stock
What is a current GRCL stock price?
Gracell Biotechnologies GRCL stock price today per share is 10.25 USD.
How to purchase Gracell Biotechnologies stock?
You can buy GRCL shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Gracell Biotechnologies?
The stock symbol or ticker of Gracell Biotechnologies is GRCL.
Which industry does the Gracell Biotechnologies company belong to?
The Gracell Biotechnologies industry is Biotechnology.
How many shares does Gracell Biotechnologies have in circulation?
The max supply of Gracell Biotechnologies shares is 96.57M.
What is Gracell Biotechnologies Price to Earnings Ratio (PE Ratio)?
Gracell Biotechnologies PE Ratio is 0.00000000 now.
What was Gracell Biotechnologies earnings per share over the trailing 12 months (TTM)?
Gracell Biotechnologies EPS is 0 USD over the trailing 12 months.
Which sector does the Gracell Biotechnologies company belong to?
The Gracell Biotechnologies sector is Healthcare.
Gracell Biotechnologies GRCL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
| NASDAQ Golden Dragon China Inde HXC | 6953.76 USD — |
-0.4
|
— — | 6882.01 USD — | 6954.44 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8504.39 USD — |
+1.34
|
— — | 8367.19 USD — | 8515.13 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}